FY2027-Q1 was strong, with revenue of ¥3,287 million and operating profit of ¥277 million, up 27.1% and 162.9%, respectively, year on year. The full-year forecasts remain unchanged at revenue of ¥13,102 million and operating profit of ¥904 million. FY2027-H1 will show whether the high profit margin was nonrecurring.
All recorded disclosures and news since the latest annual or semiannual filing. Switching watchpoints keeps the full history. Select an item to inspect its source.2026-06-25 〜 2026-11-07 · 21 of 21 items
Scroll the timeline →
Whether the operating margin can be maintained at approximately 8.4%, up from approximately 4.1% in FY2026-Q1.
Whether progress against the full-year revenue forecast will approach approximately 50% in FY2027-H1, compared with 25.1% in FY2027-Q1.
How far progress against the full-year operating profit forecast of ¥904 million will rise from 30.6% in FY2027-Q1.
Whether the company will disclose any revision to its full-year forecasts of ¥13,102 million in revenue and ¥904 million in operating profit as of FY2027-H1.
FY2027-Q1 revenue was ¥3,287 million, operating profit was ¥277 million, ordinary profit was ¥263 million, and net profit attributable to owners of the parent was ¥176 million. Year on year, revenue rose 27.1%, while operating profit increased 162.9%, ordinary profit 173.3%, and net profit 176.9%, with profit growth substantially outpacing revenue growth. The operating margin was approximately 8.4%, calculated by dividing ¥277 million by ¥3,287 million.
In the year-earlier period, revenue was ¥2,585 million and operating profit was ¥105 million, so revenue increased by ¥702 million and operating profit by ¥172 million over the year. The operating margin also improved by approximately 4.3 percentage points, from approximately 4.1% to approximately 8.4%. The company attributed the improvement in profit to the reversal of upfront costs incurred in the previous period for new store openings and new facilities, as well as contributions from existing home-visit pharmacy stores and the third and fourth Primary Care Home facilities.
The full-year forecasts are revenue of ¥13,102 million, operating profit of ¥904 million, ordinary profit of ¥843 million, and net profit of ¥631 million, with no revision as of Q1. Progress against the full-year forecasts based on Q1 results was 25.1% for revenue, 30.6% for operating profit, 31.2% for ordinary profit, and 27.9% for net profit. Although progress is ahead of a simple quarterly run rate, the comparison includes the effect of lower investment costs than in the previous period, making continued improvement through the first two quarters important.
In FY2027-H1, we will look not only for revenue growth, but also for the maintenance of an operating margin in the 8% range, the margin of the home-visit pharmacy business, ARPU for Kirari Prime, and occupancy rates and resident fees at Primary Care Home. The assessment of the first-half results will depend on whether the increase in operating profit reflects improved profitability at existing sites, rather than simply the lapse of temporary costs related to new store openings and facility launches, and whether the company maintains its full-year operating profit forecast of ¥904 million.
¥ million
Operating profit grew faster than revenue, resulting in a significant improvement in the profit margin.
Select a value or step to inspect its source.
Ordered by date. Disclosures and financial records differ from news and company threads; open each source to inspect it.
2026-11-13 · Awaiting publication
· Awaiting publication
The prior-year comparison for this event
2025-11-14 disclosed · In ¥ millions; each quarter is cumulative from the start of the fiscal year. EPS is in yen.
Latest available: FY2027 Q1
Net salesBusiness scale
5,532JPY m
YoY unavailableOperating profitCore earnings
225JPY m
YoY unavailableNewest first. The highlighted column is this event’s comparison. YoY uses the same period and accounting basis.
| Metric | FY2027 Q1 | FY2026 full year | FY2026 Q3 | FY2026 Q2Comparison | FY2026 Q1 | FY2025 full year | FY2025 Q3 |
|---|---|---|---|---|---|---|---|
| Net sales | 3,287↗ +27.2% YoY | 11,983↗ +20.0% YoY | 8,718↗ +19.9% YoY | 5,532YoY unavailable | 2,585YoY unavailable | 9,984YoY unavailable | 7,272YoY unavailable |
| Operating profit | 277↗ +163.8% YoY | 816↘ -22.4% YoY | 411↘ -39.1% YoY | 225YoY unavailable | 105YoY unavailable | 1,051YoY unavailable | 675YoY unavailable |
| Ordinary profit | 263↗ +174.0% YoY | 776↘ -24.1% YoY | 380↘ -40.5% YoY | 206YoY unavailable | 96YoY unavailable | 1,022YoY unavailable | 639YoY unavailable |
| Net income | 176↗ +179.4% YoY | 501↘ -30.3% YoY | 246↘ -37.6% YoY | 136YoY unavailable | 63YoY unavailable | 719YoY unavailable | 394YoY unavailable |
| Earnings per share | 24.82↗ +177.0% YoY | 70.38↘ -30.4% YoY | 34.61↘ -37.7% YoY | 19.1YoY unavailable | 8.96YoY unavailable | 101.12YoY unavailable | 55.54YoY unavailable |